132 related articles for article (PubMed ID: 26648239)
21. SOX4 arrests lung development in rats with hyperoxia‑induced bronchopulmonary dysplasia by controlling EZH2 expression.
Pan B; Xue X; Zhang D; Li M; Fu J
Int J Mol Med; 2017 Dec; 40(6):1691-1698. PubMed ID: 29039454
[TBL] [Abstract][Full Text] [Related]
22. SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition?
Lourenço AR; Coffer PJ
Trends Cancer; 2017 Aug; 3(8):571-582. PubMed ID: 28780934
[TBL] [Abstract][Full Text] [Related]
23. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
[TBL] [Abstract][Full Text] [Related]
25. SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients.
Song GD; Sun Y; Shen H; Li W
Tumour Biol; 2015 Jun; 36(6):4167-73. PubMed ID: 25592378
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
27. miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome.
Xu X; Zong K; Wang X; Dou D; Lv P; Zhang Z; Li H
Cell Death Dis; 2021 Apr; 12(4):350. PubMed ID: 33824274
[TBL] [Abstract][Full Text] [Related]
28. LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2.
Song Z; Zhang X; Lin Y; Wei Y; Liang S; Dong C
J Cell Mol Med; 2019 Nov; 23(11):7554-7565. PubMed ID: 31557401
[TBL] [Abstract][Full Text] [Related]
29. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer.
Huang HY; Cheng YY; Liao WC; Tien YW; Yang CH; Hsu SM; Huang PH
PLoS One; 2012; 7(12):e48637. PubMed ID: 23251334
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma.
Gao L; Antic T; Hyjek E; Gong C; Mueller J; Waxman I; DeMay RM; Reeves W
Cancer Cytopathol; 2013 Nov; 121(11):644-52. PubMed ID: 23674382
[TBL] [Abstract][Full Text] [Related]
31. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
[TBL] [Abstract][Full Text] [Related]
32. Effect of Twist and Bmi1 on intraductal papillary mucinous neoplasm of the pancreas.
Ishikawa D; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Miyake H
J Gastroenterol Hepatol; 2014 Dec; 29(12):2032-7. PubMed ID: 24909638
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer.
Shen R; Pan S; Qi S; Lin X; Cheng S
Biochem Biophys Res Commun; 2010 Apr; 394(4):1047-52. PubMed ID: 20331975
[TBL] [Abstract][Full Text] [Related]
34. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
35. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
[TBL] [Abstract][Full Text] [Related]
36. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
39. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Maftouh M; Avan A; Funel N; Paolicchi E; Vasile E; Pacetti P; Vaccaro V; Faviana P; Campani D; Caponi S; Mambrini A; Boggi U; Cantore M; Milella M; Peters GJ; Reni M; Giovannetti E
Pharmacogenomics; 2014 Apr; 15(5):609-18. PubMed ID: 24798718
[TBL] [Abstract][Full Text] [Related]
40. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
